siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells

World Journal of Gastroenterology

Volumn 19, Issue 44, 2013, Pages 8108-8113

  Zhou, Dong ^a   Yang, Jie ^a   Huang, Wei Dong ^a   Wang, Jun ^a   Zhang, Qiang ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Colon cancer; Gene therapy; Growth hormone receptor; Signaling pathway; Small interfering RNAs

Indexed keywords

FLUOROURACIL; GROWTH HORMONE RECEPTOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GROWTH HORMONE RECEPTOR GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; OPTICAL DENSITY; PERITONEAL CAVITY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR VOLUME; WESTERN BLOTTING;

COLON CANCER; GENE THERAPY; GROWTH HORMONE RECEPTOR; SIGNALING PATHWAY; SMALL INTERFERING RNAS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GROWTH HORMONE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, SOMATOTROPIN; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888581190     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i44.8108     Document Type: Article

References (25)

1. Lincoln DT, Kaiser HE, Raju GP, Waters MJ. Growth hormone and colorectal carcinoma: localization of receptors. In Vivo 2000; 14: 41-49 [PMID: 10757060]
2. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814-821 [PMID: 16116438 DOI: 10.1038/nsmb977]
3. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360: 273-277 [PMID: 12147369 DOI: 10.1016/S0140-6736(02)09519-3]
4. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J Clin Endocrinol Metab 2003; 88: 1705-1710 [PMID: 12679461 DOI: 10.1210/ jc.2002-021667]
5. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-980 [PMID: 12096082 DOI: 10.1093/jnci/94.13.972]
6. Nysom K, Holm K, Michaelsen KF, Hertz H, Müller J, Mølgaard C. Degree of fatness after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2003; 40: 239-243 [PMID: 12555252 DOI: 10.1002/mpo.10260]
7. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 2000; 19: 2585-2597 [PMID: 10851057 DOI: 10.1038/sj.onc.1203526]
8. Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol 2006; 36: 1-7 [PMID: 16461922 DOI: 10.1677/jme.1.01933]
9. Banerjee I, Clayton PE. Growth hormone treatment and cancer risk. Endocrinol Metab Clin North Am 2007; 36: 247-263 [PMID: 17336744 DOI: 10.1016/j.ecl.2006.11.007]
10. Jeay S, Sonenshein GE, Postel-Vinay MC, Kelly PA, Baixeras E. Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways. Mol Cell Endocrinol 2002; 188: 1-7 [PMID: 11911939 DOI: 10.1016/S0303-7207(02)00014-X]
11. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98: 315-327 [PMID: 16541323 DOI: 10.1007/s10549-006-9168-1]
12. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference--new hope for a highly specific cancer treatment? Cancer Cell 2002; 2: 167-168 [PMID: 12242146 DOI: 10.1016/S1535-6108(02)00129-0]
13. Lassus P, Rodriguez J, Lazebnik Y. Confirming specificity of RNAi in mammalian cells. Sci STKE 2002; 2002: pl13 [PMID: 12198178 DOI: 10.1126/scisignal.1472002pl13]
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]
15. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, FinchJones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]
16. Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 2007; 63: 111-124 [PMID: 17555981 DOI: 10.1016/ j.critrevonc.2007.04.001]
17. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 2003; 124: 293-302 [PMID: 12557135 DOI: 10.1053/gast.2003.50057]
18. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007; 13: 1000-1009 [PMID: 17289896 DOI: 10.1158/1078-0432.CCR-06-1910]
19. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006; 64: 115-121 [PMID: 16430706 DOI: 10.1111/j.1365-2265.2005.02404.x]
20. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGFbinding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 2001; 37: 2257-2263 [PMID: 11677116 DOI: 10.1016/ S0959-8049(01)00269-6]
21. Wu X, Wan M, Li G, Xu Z, Chen C, Liu F, Li J. Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. Eur J Cancer 2006; 42: 888-894 [PMID: 16516462 DOI: 10.1016/j.ejca.2005.12.012]
22. Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA 2007; 104: 13331-13336 [PMID: 17690250 DOI: 10.1073/pnas.0600181104]
23. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE, Ellis LM. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82: 1377-1389 [PMID: 12379772]
24. Matsui K, Sasaki Y, Komatsu T, Mukai M, Kikuchi J, Aoyama Y. RNAi gene silencing using cerasome as a viral-size siRNA-carrier free from fusion and cross-linking. Bioorg Med Chem Lett 2007; 17: 3935-3938 [PMID: 17502138 DOI: 10.1016/ j.bmcl.2007.04]
25. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP, Nordheim A. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t (8; 21)-positive leukemic cells. Blood 2003; 101: 3157-3163 [PMID: 12480707 DOI: 10.1182/ blood-2002-05-1589]